Welcome to Talking Precision Medicine (TPM podcast) — the podcast in which we discuss the future of healthcare and health technology, and how advances in data and data science are fueling the next industrial revolution.

Today my guest is Joydeep Goswami, newly appointed President and CEO of the storied biotechnology company LGC. Joydeep is also a strategy advisor to Genialis. Join us as we discuss his remarkable career and lessons learned at each step of the way.

Come on in and have a listen.

Episode highlights:

Career insights

“The things that have enriched me the most are things that I didn’t know I didn’t know, right? In any new job, there are things you know, things you know you don’t know, and then there are things where you go, ‘Wow, I had no clue I would be learning X, Y, and Z.’ And I think that has always been the most enriching part of any new role I’ve taken on.”

  • Joydeep Goswami started his career in consulting, followed by leadership roles at Invitrogen, Life Technologies, Thermo Fisher, and Illumina
  • Moving to Japan after the Tsumani in 2011 provided Joydeep a firsthand lesson in the importance of listening and adapting to cultural business norms
  • A brief career break after Illumina helped clarify personal priorities and improve decision-making for future opportunities

“I got the time to just disengage and start thinking about what really made me happy and what I really wanted from things. And you know, I had a list of things—this is what I’m looking for in a new role. And what it gave me, as I started getting into this, was this weird ability to just say no to a lot of things because they didn’t fit those criteria. And that was amazing, right?”

Joydeep’s new role at LGC Group

“The goal for LGC is to serve customers by enabling basic research, diagnostics, therapeutics, and, fundamentally, safety. Our motto is to help make the world safer, and that’s where our products are focused. LGC operates in three key areas: diagnostics/genomics, analytical standards, and CRO/CMO services in gene and cell therapy.”

  • Joydeep Goswami is now working as President and CEO of LGC Group.
  • The company’s mission is to enable safer healthcare and research by providing high-quality reference materials and standards.

“I see my role as working with my team as a thought partner and really helping to bring perspective from my background that helps them kind of see the forest through the trees, as it were, right? And to look around corners a little bit, ask the right questions, so that we can collectively reach the right answers.”

A look into the future

“The question is, you know, how do you balance the speed at which these innovations are coming in with having the appropriate level of confidence? And I do agree with folks who say, you know, overregulation is not a good thing, right, because it stifles innovation. And especially in this particular area, that would be a mistake. But I don’t think I’ve heard anyone talk about, oh, this is just going to replace physicians or replace experts, right? They should be used as a tool.”

  • Following JP Morgan 2025, Joydeep Goswami believes the life sciences sector is experiencing cautious optimism. Pharma and biotech R&D investment will play a crucial role in determining market momentum for the coming years.
  • The FDA has been proactive in approving AI applications, though challenges remain in balancing innovation with appropriate oversight.
  • Joydeep believes AI should be viewed as an augmenting tool for physicians and researchers, not a replacement for human expertise.

This has been Talking Precision Medicine. Please subscribe and share our podcast with your colleagues, leave a comment or review, and stay tuned for the next episode. Until then you can explore our TPM podcast archive and listen to interesting guests from our past conversations.

Listen on Spotify badge
Listen on Apple Podcasts badge
Listen on YouTube Music badge
Share this story, choose your platform!